Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 5/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.45 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991962 | 0.96 | MEN1 (0.46) | MAOBALDH1A1PPARDPPARAPPARG | |
| SCHEMBL21992726 | 0.92 | MAOB (0.60) | MAOBPPARDPPARAPPARGMME | |
| SCHEMBL21991581 | 0.85 | ALDH1A1 (0.48) | MAOBALDH1A1PPARDMMEACE | |
| SCHEMBL16379339 | 0.84 | PPARA (0.49) | MAOBALDH1A1PPARDPPARAPPARG | |
| SCHEMBL21991930 | 0.84 | PPARD (0.49) | MAOBALDH1A1PPARDPPARAPPARG | |
| SCHEMBL21992697 | 0.84 | MAOB (0.44) | MAOBALDH1A1PPARDPPARAPPARG | |
| SCHEMBL21991328 | 0.83 | KDM4E (0.44) | MAOBALDH1A1PPARAPPARGMME | |
| SCHEMBL21992729 | 0.82 | ALDH1A1 (0.45) | MAOBALDH1A1PPARD | |
| SCHEMBL21991932 | 0.81 | LDHA (0.50) | ALDH1A1PPARAPPARGFFAR1 | |
| SCHEMBL21991335 | 0.80 | PPARA (0.55) | MAOBALDH1A1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885ALDH1A1 932/4885PPARD 760/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | MAOB 3946/4885ALDH1A1 932/4885PPARD 760/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885ALDH1A1 932/4885PPARD 760/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885ALDH1A1 932/4885PPARD 760/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885ALDH1A1 932/4885PPARD 760/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAOB 3946/4885ALDH1A1 932/4885PPARD 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.